BillionToOne has partnered with Culmination Bio to verify the effectiveness of two oncology tests, Northstar Select, for therapy selection for stage III or IV cancer, and Northstar Response, which measures patient responses to treatment.
The partnership will utilize Culmination’s patient clinical data and biospecimens to validate these tests for regulatory approval. In addition, BillionToOne will employ tissue samples collected by Culmination from Intermountain's patient population to host both validation studies.
Culmination Bio is a biotechnology company that specializes in developing a data intelligence platform that combines biospecimens with clinical data. Its product, the Culmination Intelligence Platform, allows analysis across various biopharmaceutical research domains.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.